5 Best upcoming ASX Healthcare stocks
Team Veye | 12-Sep-2025
Telix Pharmaceuticals Limited (ASX: TLX)
showed strong growth in H1 FY2025. Its revenue went up 63% from the H1FY2024 to U$390.4 million. Most of this came from Illuccix sales of U$305.8 million and also from the RLS acquisition which added U$79.0 million. Adjusted EBITDA stood at U$21.1 million even though the company spent heavily on R&D with U$81.6 million invested. It posted a small net loss after tax of U$2.3 million. The cash position still remained solid at U$207.2 million. On the pipeline side the company is moving forward with Zircaix and Pixclara and also the ProstACT Global Phase 3 trial. Looking ahead Telix seems well placed with many late stage programs close to commercialisation.
Neuren Pharmaceuticals Limited (ASX: NEU)
posted a profit after tax of about A$15 million in H1 FY2025 compared to A$8 million in H1 FY2024. This growth mainly came from higher DAYBUE royalties which came in at A$28.3 million. The company also finished a A$50 million buyback at an average price of A$12.27 per share. EPS went up to 11.9c. Cash and investments stood at A$300 million by June 2025 which is higher than A$222 million back in December 2024. Partner company Acadia showed DAYBUE US net sales of U$180.7 million in H1. The pipeline is also strong with a Phase 3 trial in Phelan-McDermid, FDA Fast Track for Pitt Hopkins and new work starting in HIE and SYNGAP1.
Clinuvel Pharmaceuticals (ASX: CUV)
has reported its 9th straight year of profit in FY2025. The company’s revenue grew 10% to A$105.3 million while NPAT went up 2% to A$36.2 million. EBITDA margin stayed solid due to strict cost control and cash reserves jumped 22% to A$224.1 million which shows a very strong debt free balance sheet. The company also declared its 8th yearly dividend of 5cps fully franked. Around 40% of revenue is still being put back into R&D with pipeline projects such as SCENESSE for EPP and vitiligo, NEURACTHEL and also photocosmetic products. Looking ahead the company is expecting EMA dosage expansion, approval from Health Canada and also a NASDAQ uplisting in Q4 2025.
PolyNovo Limited (ASX: PNV)
had a record revenue in FY2025 of A$129.2 million which is 23.3% higher than FY2024.This growth mainly came from strong commercial sales of A$118.6 million. NPAT jumped 151% to A$13.2 million and EBITDA increased to A$11.2 million compared to A$3.6 million last year. NovoSorb MTX kept growing in hernia and soft tissue markets with more than 84,000 patient treatments across 46 countries. The balance sheet got stronger as the company invested A$30.3 million in capex. The aim forward is to look at deeper U.S market reach and more new product launches worldwide to keep the growth going.
Orthocell Limited (ASX: OCC)
posted a record revenue of A$9.2 million in FY2025 which was 36.4% higher than last year. The June quarter alone gave sales of A$2.75 million making it the fifth straight quarter of record sales. Product sales jumped 74.2% to A$5.2 million as demand was strong for Remplir and Striate. Cash reserves went up to A$28.6 million with no debt. The company also did a A$17 million placement to fast track its US expansion after FDA approval for Remplir which targets the U$1.6 billion nerve repair market in US Looking forward Orthocell wants to expand more in new markets like US, Canada and Singapore where distributor networks are already in place in 25 states.
(Source: Company Announcements)
Disclaimer
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
